It’s about time…

Dymista®

A next step for nasal and ocular symptom control1

Dymista® is clinically proven to relieve the symptoms of moderate to severe allergic rhinitis in studies involving more than 4,600 patients.2,3,4

  • …to take allergic rhinitis seriously.
  • …to treat uncontrolled allergic rhinitis with a dual action formulation in a single device.
  • …to offer rapid symptom relief with Dymista®.5,6
    - First relief of nasal symptoms observed at 5 minutes in an allergen exposure chamber6
    - Within 15 minutes, 60% of patients achieved clinically relevant relief of nasal symptoms6
  • …to get allergic rhinitis under control all year round - Dymista® is suitable for long term use.6
  • …to follow national, international guidelines and advice on when to use Dymista®.7,8,9,10

The Summary of Product Characteristics (SmPC) for Dymista lists epistaxis, headache, dysgeusia (unpleasant taste), unpleasant smell as very common or common adverse reactions.6
Please refer to the Summary of Product Characteristics (SmPC) before prescribing, particularly in relation to adverse reactions, precautions, contra-indications and method of use.

References

  • Meltzer E, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013; 161(4): 369-377.
  • Price D, et al. MP29-02 a novel intranasal therapy for the treatment of chronic rhinitis: safety data from a 12 month-trial. Presented at EEAACI, Geneva, 16-20 June 2013.
  • Carr W, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012; 129(5):
    1282-1289.
  • Hampel FC, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol. 2010; 105(2): 168-173.
  • Bousquet J, et al. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber.
    J Allergy Clin Immunol Pract. 2018; 6(5): 1726-1732.
  • Dymista® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/9450. Last accessed: November 2023.
  • Scadding GK, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy 2017; 47(7): 856-889.
  • Scottish Medicine Consortium (SMC). Available at: https://www.scottishmedicines.org.uk/medicines-advice/azelastine-hydrochloride-plus-fluticasone-propionate-dymista-abbreviatedsubmission-92113/. Last accessed: November 2023.
  • Brożek JL, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017; 140(4): 950-958.
  • Lipworth B, et al. An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel. NPJ Prim Care Respir Med. 2017; 27(1): 3.

DYM-2023-0761 November 2023

The website you are trying to access is designed for healthcare professionals in the UK, the content is not designed for the general public.

Are you a UK healthcare professional?

YES
NO

Viatris Connect is an online platform for UK health Professionals.

Across the website you will find news, blogs and product information.

Register to Viatris Connect today

Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients.

REGISTER NOW

Please continue to report suspected adverse drug reactions and device failures with any medicine or vaccine to the MHRA through the Yellow Card Scheme.

It is easiest and quickest to report adverse drug reactions and device failures online via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively, you can report via some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) or by calling the Commission on Human Medicines (CHM) free phone line: 0800-731-6789.
Adverse reactions/events and device failures should also be reported to MAH at e-mail address: pv.uk@viatris.com.

This website is owned and managed by Viatris. For more information visit viatris.co.uk


This site is intended for UK healthcare professionals only. If you're a patient who has been prescribed Dymista® (azelastine hydrochloride/fluticasone propionate), please ​click here.

Dymista® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.​

Copyright © 2023 Viatris Inc All rights reserved. Dymista® is a registered trademark of Viatris Inc.

Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781)

Mylan Logo